Study of how ontunisertib is processed in healthy men
Part of Digestive system clinical trials.
This study tests how a new drug, ontunisertib, is processed by the body and eliminated. Healthy men will take a single dose with a tiny radioactive tracer so researchers can track the drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man between 30 and 65 years old.
- You must be in good general health, with no significant medical problems.
- Your body mass index (BMI) must be between 18.0 and 29.9.
- You must agree to use effective contraception for 93 days after the last dose.
- You cannot have any history of serious stomach, liver, kidney, or mental health issues.
- You cannot have had significant radiation exposure in the past year or five years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called ontunisertib versus a placebo in people with Crohn's disease that has caused narrowing (strictures) in the small intestine. It aims to see if the drug can help without needing surgery or other procedures.
This study gives healthy men a single dose of a new medicine to see how the body absorbs, uses, and removes it over time. It helps researchers understand the drug's safety and behavior before it is tested in patients.
This study examines how a new drug (called HRS-1780) is processed and eliminated by the body using a special radioactive label. It will help researchers understand the drug’s behavior to guide future studies.
This study tracks how a new drug, called FXS4640, moves through the body in healthy men. It uses a small amount of radioactivity to follow the drug, which helps researchers understand how it is absorbed and cleared. Participation involves staying at the clinic for several days for tests and samples.
This trial tests whether a new drug is safe in healthy men. It is a ''first-in-human'' study, so it helps determine the right dose and check for side effects.
This study is testing how a new drug is processed by the body in healthy men. It will help researchers understand the drug's effects and safety before it is tested in patients.
Hear when a new Fibrostenotic Crohn's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.